Literature DB >> 10629089

Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells.

J Usuda1, N Saijo, K Fukuoka, H Fukumoto, H J Kuh, T Nakamura, Y Koh, T Suzuki, F Koizumi, T Tamura, H Kato, K Nishio.   

Abstract

UCN-01 (7-hydroxystaurosporine) inhibits the growth of various malignant cell lines in vitro and in vivo. In this study, a human small cell lung carcinoma subline resistant to UCN-01, SBC-3/UCN, was established and characterized. SBC-3/UCN cells showed 8-fold greater resistance to the UCN-01-induced growth-inhibitory effect than the parent cells, SBC-3. No UCN-01-induced G1 accumulation in SBC-3 cells was observed in SBC-3/UCN cells and decreased expression of phosphorylated RB protein was found in SBC-3 cells. Neither basal expression nor induction of p21(Cip1) by UCN-01 treatment was detected in the SBC-3/UCN cell line. An inhibitory effect of UCN-01 on CDK2 activity, which is mediated by p21(Cip1)/CDK2 complex formation upon UCN-01 treatment, was observed in SBC-3 but not in SBC-3/UCN cells. SBC-3/UCN showed higher CDK6 activity than SBC-3 cells. UCN-01 did not inhibit the CDK4 and CDK6 activities in both cells. We screened the cell cycle regulatory molecules associated with G(1)/S progression and found a remarked decrease in interferon regulatory factor 1 (IRF-1), which is known to cooperate with p53 in p21(Cip1) induction. Our results suggest that p21(Cip1) regulation via the IRF-1-associated pathway may represent a major determinant of UCN-01-induced growth inhibition in human lung cancer cells. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629089     DOI: 10.1002/(sici)1097-0215(20000115)85:2<275::aid-ijc20>3.0.co;2-5

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.

Authors:  Antonio Jimeno; Michelle A Rudek; Thomas Purcell; Daniel A Laheru; Wells A Messersmith; Janet Dancey; Michael A Carducci; Sharyn D Baker; Manuel Hidalgo; Ross C Donehower
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-12       Impact factor: 3.333

2.  A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies.

Authors:  Paula M Fracasso; Kerry J Williams; Ronald C Chen; Joel Picus; Cynthia X Ma; Matthew J Ellis; Benjamin R Tan; Timothy J Pluard; Douglas R Adkins; Michael J Naughton; Janet S Rader; Matthew A Arquette; James W Fleshman; Allison N Creekmore; Sherry A Goodner; Lisa P Wright; Zhanfang Guo; Christine E Ryan; Yu Tao; Eliane M Soares; Shi-Rong Cai; Li Lin; Janet Dancey; Michelle A Rudek; Howard L McLeod; Helen Piwnica-Worms
Journal:  Cancer Chemother Pharmacol       Date:  2010-08-08       Impact factor: 3.333

3.  A novel in silico reverse-transcriptomics-based identification and blood-based validation of a panel of sub-type specific biomarkers in lung cancer.

Authors:  Debmalya Barh; Neha Jain; Sandeep Tiwari; John K Field; Elena Padin-Iruegas; Alvaro Ruibal; Rafael López; Michel Herranz; Antaripa Bhattacharya; Lucky Juneja; Cedric Viero; Artur Silva; Anderson Miyoshi; Anil Kumar; Kenneth Blum; Vasco Azevedo; Preetam Ghosh; Triantafillos Liloglou
Journal:  BMC Genomics       Date:  2013-10-25       Impact factor: 3.969

4.  UCN-01 induces S and G2/M cell cycle arrest through the p53/p21(waf1) or CHK2/CDC25C pathways and can suppress invasion in human hepatoma cell lines.

Authors:  Guoyi Wu; Nan Lin; Linan Xu; Bo Liu; Mark A Feitelson
Journal:  BMC Cancer       Date:  2013-03-28       Impact factor: 4.430

5.  FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis.

Authors:  Hamza M Al-Tamari; Swati Dabral; Anja Schmall; Pouya Sarvari; Clemens Ruppert; Jihye Paik; Ronald A DePinho; Friedrich Grimminger; Oliver Eickelberg; Andreas Guenther; Werner Seeger; Rajkumar Savai; Soni S Pullamsetti
Journal:  EMBO Mol Med       Date:  2018-02       Impact factor: 12.137

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.